Randomized patients underwent one of the following priming strategies : transdermal testosterone ( 20 g/kg/d ) , transdermal estradiol ( 200 g/d ) , or combined estrogens and oral contraceptive pills ( 30 g of ethinyl estradiol plus 150 g of desogestrel administered during the luteal phase of two consecutive cycles ) and 4 mg/d of estradiol valerate during the follicular phase between them .